volatile-organic-compounds
(2)
SpotitEarly
SpotitEarly is a healthtech company building an accessible, non-invasive early cancer detection service that combines trained scent-detection beagles with an AI platform to analyze volatile organic compounds (VOCs) in a person's breath. Users collect a breath sample at home and mail it to the company's lab, where beagles screen for cancer-linked odors and SpotitEarly's proprietary LUCID bio-AI platform digitizes and interprets the dogs' behavioral signals. A double-blind clinical study of 1,400 people, published in Nature's Scientific Reports, reported 94% sensitivity and specificity across the four most common cancers - breast, colorectal, lung, and prostate. Founded in Israel and now launching in the U.S., the company aims to make routine multi-cancer pre-screening affordable, at roughly $250 for a single test.
Shlomi Madar
Shlomi Madar is the CEO of SpotitEarly, an Englewood, New Jersey biotech developing a non-invasive, breath-based multi-cancer screening test that pairs trained scent-detection dogs with a deep-learning platform. He holds a PhD in cancer research from the Weizmann Institute of Science and has spent more than fifteen years in life sciences and healthcare, previously serving as VP of Strategic Alliances at OncoHost and working on the Weizmann Institute's innovation arm. In May 2025 SpotitEarly closed a $20.3M Series A behind clinical results the company reports at roughly 94% sensitivity and specificity across four cancer types.